|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue显示文摘 | Kirsten Muri Boberg Roger W. Chapman Gideon M. Hirschfield Ansgar W. Lohse Michael P. Manns Erik Schrumpf | 2010 | Journal of Hepatology2010，，2： | 4 |
| 2 | Unmet clinical need in autoimmune liver diseases显示文摘 | Jessica K. Dyson Gwilym Webb Gideon M. Hirschfield Ansgar Lohse Ulrich Beuers Keith Lindor David E.J. Jones | 2014 | Journal of Hepatology2014，，： | 2 |
| 3 | The Phenotypic Expression of Inflammatory Bowel Disease in Patients with Primary Sclerosing Cholangitis Differs in the Distribution of Colitis显示文摘 | David F. Schaeffer Lay Lay Win Sara Hafezi-Bakhtiari Maria Cino Gideon M. Hirschfield Hala El-Zimaity | 2013 | Digestive Diseases and Sciences2013，，9： | 2 |
| 4 | The Genetics of Complex Cholestatic Disorders显示文摘 | Gideon M. Hirschfield Roger W. Chapman Tom H. Karlsen Frank Lammert Konstantinos N. Lazaridis Andrew L. Mason | 2013 | Gastroenterology2013，，7： | 2 |
| 5 | Portal hypertension in polycystic liver disease patients does not affect wait-list or immediate post-liver transplantation outcomes显示文摘AIM To establish the impact of portal hypertension(PH) on wait-list/post-transplant outcomes in patients with polycystic liver disease(PCLD) listed for liver transplantation. METHODS A retrospective single-centre case controlled study of consecutive patients listed for liver transplantation over 12 years was performed from our centre. PH in the PCLD cohort was defined by the one or more of following parameters:(1) presence of radiological or endoscopic documented varices from our own centre or the referral centre;(2) splenomegaly(> 11 cm) on radiology inabsence of splenic cysts accounting for increased imaging size;(3) thrombocytopenia(platelets < 150 × 109/L); or(4) ascites without radiological evidence of hepatic venous outflow obstruction from a single cyst. RESULTS Forty-seven PCLD patients(F: M = 42: 5) were listed for liver transplantation(LT)(single organ, n = 35; combined liver-kidney transplantation, n = 12) with 19 patients(40.4%) having PH. When comparing the PH group with non-PH group, the mean listing age(PH group, 50.6(6.4); non-PH group, 47.1(7.4) years; P = 0.101), median listing MELD(PH group, 12; non-PH group, 11; P = 0.422) median listing UKELD score(PH group, 48; non-PH group, 46; P = 0.344) and need for renal replacement therapy(P = 0.317) were similar. In the patients who underwent LT alone, there was no difference in the duration of ICU stay(PH, 3 d; non-PH, 2 d; P = 0.188), hospital stay length(PH, 9 d; non-PH, 10 d; P = 0.973), or frequency of renal replacement therapy(PH, 2/8; non-PH, 1/14; P = 0.121) in the immediate post-transplantation period. CONCLUSION Clinically apparent portal hypertension in patients with PCLD listed for liver transplantation does not appear to have a major impact on wait-list or peri-transplant morbidity. | Neil Rajoriya Dhiraj Tripathi Joanna A Leithead Bridget K Gunson Sophie Lord James W Ferguson Gideon M Hirschfield | 2016 | World Journal of Gastroenterology2016，22，45： | 2 |
| 6 | Targeting C-reactive protein for the treatment of cardiovascular disease 显示文摘 | PepysMB Hirschfield GM Tennent GA | 2006 | Nature2006，440，7088： | 1 |
| 7 | C- reactive protein: a critical update显示文摘 | Pepys MB Hirschfield GM | 2003 | Clin Invest2003，111，12： | 1 |
| 8 | C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease显示文摘 | Danesh J Wheeler J G Hirschfield G M | 2004 | N Engl J Med2004，350，： | 1 |
| 9 | The immu- nogenicity and safety of a quadrivalent live attenuated influenza vaccine in children显示文摘 | BLOCK SL FALLOON J HIRSCHFIELD JA | 2012 | Pediatr Inject Dis J2012，，： | 1 |
| 10 | Novel therapeutic targets in primary biliary cirrhosis显示文摘 | Dyson JK Hirschfield GM Adams DH | 2015 | Nat Rev Gastroenterol Hepatol2015，12，3： | 1 |
| 11 | C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease显示文摘 | DANESH J WHEELER J G HIRSCHFIELD G M | 2004 | N Engl J Med2004，350，： | 1 |
| 12 | C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease 显示文摘 | Danesh J Wheeler JG Hirschfield GM | 2004 | N Engl J Med2004，350，14： | 1 |
| 13 | Angiographic-guided embolization of metastatic invasive mole显示文摘 | Method MW Hirschfield M Everette HE | 1996 | Gynecol Oncol1996，61，3： | 1 |
| 14 | C-reactive protein: a critical update 显示文摘 | Pepys MB Hirschfield GM | 2003 | J Clin Invest2003，111，12： | 1 |
| 15 | C-reactive protein and other circuhating markers of inflammation in the prediction of coronary heart disease显示文摘 | Danesh J Wheeler JG Hirschfield GM | 2004 | N Engl J Med2004，350，： | 1 |
| 16 | C-reactive protein:a critical update显示文摘 | Pepys MB Hirschfield GM | | 0，，： | 1 |
| 17 | Efficacy of obeticholic Acid in patients with primary biliary cirrhosis and inadequate re- sponse to ursodeoxycholic Acid显示文摘 | Hirschfield GM Mason A Luketic V | 2015 | Gastroenterology2015，148，： | 1 |
| 18 | Targeting C reactive protein for the treatment of cardiovascular disease 显示文摘 | Pepys MB Hirschfield GM Tennent GA | 2006 | Nature2006，440，7088： | 1 |
| 19 | C-reactive protein: a critical update 显示文摘 | Peps MB Hirschfield GM | 2003 | J Clin Invest2003，111，12： | 1 |
| 20 | C reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease显示文摘 | DANESH J WHEELER J G HIRSCHFIELD G M | 2004 | New England J Med2004，350，14： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员